Inclusion Criteria:  Participants must have one of the following histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumor types:  High-grade serous epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer HER2-negative, HR positive breast cancer Triple-negative breast cancer (TNBC) Endometrial carcinoma Squamous non-small cell lung cancer (Sq-NSCLC) Cholangiocarcinoma or gallbladder carcinoma Parts A and B: Participants must have disease that is relapsed or refractory or be intolerant to SOC therapies, and, in the judgement of the investigator, should have no appropriate SOC therapeutic option Part C: Subjects must have disease that is relapsed or refractory or be intolerant to SOC therapies, unless contraindicated Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 Measurable disease per RECIST version 1.1 at baseline  Exclusion Criteria:  History of another malignancy within 3 years before the first dose of study drug. Any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.  Known active central nervous system metastases. Participants with previously treated brain metastases may participate provided they:  are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment have no new or enlarging brain metastases and are off corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to the first dose of study treatment. Carcinomatous meningitis Previous receipt of an MMAE-containing agent or an agent targeting B7-H4 Pre-existing neuropathy ≥ Grade 2 per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version5.0 Corneal disease or injury requiring treatment or active monitoring